Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality in both developing and developed countries. Dyslipidemia, including hypercholesterolemia, hypertriglyceridemia and hypoalphalipoproteinemia, is the major molecular basis of the pathogenesis.
Although there are many risk factors associated with ASCVD, the causal link between dyslipidemia and ASCVD has been well evidenced, leading to different therapeutic approaches targeting dyslipidemia in pre-clinical studies. However, given the complexity of lipid metabolism, the precise molecular mechanisms under the dyslipidemic conditions have not been completely understood; few of the treatments with lipid-lowering agents yield satisfactory consequences in clinical trials. Based on the controversial results reported previously from both experimental animal models and clinical trials, novel molecular pathways regulating lipid metabolism in vitro and in vivo, especially cholesterol and triglyceride, should be further investigated in future studies to meet the requirement of translational study and precise medicine.
With this research topic, we aim to provide new insight into the molecular mechanism regulating lipid metabolism in vitro, including cholesterol and triglyceride. This would help to identify new therapeutic targets to treat dyslipidemia and ASCVD, which could be translated into clinical trials in near future.
This research topic also aims to encourage the application of animal models with different species, including humanized or human-like animal models, for the study of dyslipidemia and ASCVD and discuss the most recent advancements in the field of lipid metabolism and the related ASCVD, covering basic and clinical aspects.
- Environmental factors of dyslipidemia, including hypercholesterolemia and hypertriglyceridemia
- Genetic factors of dyslipidemia, including hypercholesterolemia and hypertriglyceridemia and hypoalphalipoproteinemia
- Molecular mechanism of cholesterol regulation in vitro and in vivo
- Molecular mechanism of triglyceride regulation in vitro and in vivo
- Identification of new lipid-lowering compounds in vitro
- Application of animal models for dyslipidemia and ASCVD
- New insight into the management of dyslipidemia and ASCVD
- New pharmacological approaches to treat dyslipidemia and ASCVD
- Systematic review of the advancement of dyslipidemia and ASCVD
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality in both developing and developed countries. Dyslipidemia, including hypercholesterolemia, hypertriglyceridemia and hypoalphalipoproteinemia, is the major molecular basis of the pathogenesis.
Although there are many risk factors associated with ASCVD, the causal link between dyslipidemia and ASCVD has been well evidenced, leading to different therapeutic approaches targeting dyslipidemia in pre-clinical studies. However, given the complexity of lipid metabolism, the precise molecular mechanisms under the dyslipidemic conditions have not been completely understood; few of the treatments with lipid-lowering agents yield satisfactory consequences in clinical trials. Based on the controversial results reported previously from both experimental animal models and clinical trials, novel molecular pathways regulating lipid metabolism in vitro and in vivo, especially cholesterol and triglyceride, should be further investigated in future studies to meet the requirement of translational study and precise medicine.
With this research topic, we aim to provide new insight into the molecular mechanism regulating lipid metabolism in vitro, including cholesterol and triglyceride. This would help to identify new therapeutic targets to treat dyslipidemia and ASCVD, which could be translated into clinical trials in near future.
This research topic also aims to encourage the application of animal models with different species, including humanized or human-like animal models, for the study of dyslipidemia and ASCVD and discuss the most recent advancements in the field of lipid metabolism and the related ASCVD, covering basic and clinical aspects.
- Environmental factors of dyslipidemia, including hypercholesterolemia and hypertriglyceridemia
- Genetic factors of dyslipidemia, including hypercholesterolemia and hypertriglyceridemia and hypoalphalipoproteinemia
- Molecular mechanism of cholesterol regulation in vitro and in vivo
- Molecular mechanism of triglyceride regulation in vitro and in vivo
- Identification of new lipid-lowering compounds in vitro
- Application of animal models for dyslipidemia and ASCVD
- New insight into the management of dyslipidemia and ASCVD
- New pharmacological approaches to treat dyslipidemia and ASCVD
- Systematic review of the advancement of dyslipidemia and ASCVD
